Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

被引：0
|
作者：
Claudia A. Chiriboga
Claudio Bruno
Tina Duong
Dirk Fischer
Eugenio Mercuri
Janbernd Kirschner
Anna Kostera-Pruszczyk
Birgit Jaber
Ksenija Gorni
Heidemarie Kletzl
Imogen Carruthers
Carmen Martin
Francis Warren
Renata S. Scalco
Kathryn R. Wagner
Francesco Muntoni
机构：
[1] Columbia University Irving Medical Center,Department of Neurology
[2] University of Genoa,Centre of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health
[3] Stanford University,DINOGMI
[4] University Children’s Hospital Basel,Department of Neurology
[5] University of Basel,Division of Neuropediatrics
[6] Fondazione Policlinico Gemelli IRCCS,Pediatric Neurology Institute, Catholic University and Nemo Pediatrico
[7] Medical Center-University of Freiburg,Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine
[8] Medical University of Warsaw,Department of Neurology
[9] ERN EURO-NMD,Roche Pharmaceutical Research and Early Development
[10] Pharma Development,Product Development Neuroscience
[11] Safety,The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre
[12] F. Hoffmann-La Roche Ltd,undefined
[13] PDMA Neuroscience and Rare Disease,undefined
[14] F. Hoffmann-La Roche Ltd,undefined
[15] Roche Innovation Center Basel,undefined
[16] Roche Products Ltd,undefined
[17] F. Hoffmann-La Roche Ltd,undefined
[18] Great Ormond Street Institute of Child Health University College London,undefined
[19] and Great Ormond Street Hospital Trust,undefined
来源：
Neurology and Therapy | 2023年 / 12卷
关键词：
Evrysdi; Pharmacodynamics; Risdiplam; Safety; Spinal muscular atrophy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [41] Rapid risdiplam initiation in newborns with spinal muscular atrophy (SMA): a multicenter, retrospective cohort study
    Goedeker, N.
    Dierker, A.
    Felker, M.
    Lakhotia, A.
    Rogers, A.
    Zaidman, C.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [42] How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy
    Agosto, Caterina
    Benedetti, Francesca
    Salamon, Eleonora
    Mercante, Anna
    Papa, Simonetta
    Giacomelli, Luca
    Santini, Anna
    Benini, Franca
    ACTA PAEDIATRICA, 2023, 112 (02) : 311 - 312
  • [43] RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)
    Finkel, R.
    Farrar, M.
    Vlodavets, D.
    Zanoteli, E.
    Al-Muhaizea, M.
    Nelson, L.
    Prufer, A.
    Servais, L.
    Wang, Y.
    Fisher, C.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Scalco, R.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S85 - S86
  • [44] RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)
    Finkel, R.
    Farrar, M.
    Servais, L.
    Vlodavets, D.
    Zanoteli, E.
    Al-Muhaizea, M.
    Prufer, A.
    Nelson, L.
    Fischer, C.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Gaki, E.
    Fontoura, P.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S88 - S88
  • [45] Long-term follow-up study in patients with spinal muscular atrophy (SMA) receiving risdiplam treatment
    Tanvir, I
    Tam, S.
    O'Donnell, D.
    Shapouri, S.
    Lim, E.
    Shah, R.
    Sun, C.
    Seth, G.
    ANNALS OF NEUROLOGY, 2023, 94 : S119 - S119
  • [46] Preliminary Evidence for Pharmacodynamics Effects of RG7916 in JEWELFISH, a Study in Patients with Spinal Muscular Atrophy who Previously Participated in a Study with Another SMN2-Splicing Targeting Therapy
    Chiriboga, Claudia
    Mercuri, Eugenio
    Fischer, Dirk
    Kraus, Dominik
    Alexander, Monika
    Armstrong, Gillian
    Kletzl, Heidemarie
    Gerber, Marianne
    Cleary, Yumi
    Bergauer, Tobias
    Gorni, Ksenija
    Khwaja, Omar
    NEUROLOGY, 2018, 90
  • [47] COST-EFFECTIVENESS OF RISDIPLAM FOR PATIENTS WITH TYPES 1-3 SPINAL MUSCULAR ATROPHY (SMA) IN FRANCECOST-EFFECTIVENESS OF RISDIPLAM FOR PATIENTSWITH TYPES 1-3 SPINAL MUSCULAR ATROPHY (SMA) IN FRANCE
    Boussahoua, M.
    Sutherland, C. S.
    Aponte, Ribero, V
    Enache, R.
    Le Lay, K.
    Le Dissez, C.
    Chevalier, J.
    VALUE IN HEALTH, 2022, 25 (12) : S87 - S87
  • [48] LONG-TERM FOLLOW-UP STUDY OF RISDIPLAM IN PARTICIPANTS WITH SPINAL MUSCULAR ATROPHY (WeSMA)
    Tanvir, Imran
    Lim, Elise
    Shapouri, Sheila
    Shah, Rushabh
    Sun, Christy
    Seth, Gaurav
    MUSCLE & NERVE, 2024, 70 (03) : 603 - 603
  • [49] Motor unit gains in treated spinal muscular atrophy patients
    Sumner, Charlotte J.
    Sumner, Austin J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (01): : 6 - 6
  • [50] A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy
    Powell, Jeffrey C.
    Meiling, James B.
    Cartwright, Michael S.
    MUSCLE & NERVE, 2024, 69 (02) : 179 - 184
12345